$51 Million Vaccine Revenue Partnership Announced in India

Dr. Reddy's Laboratories Ltd. today announced that it has entered into an exclusive partnership with Sanofi Healthcare India Private Limited to promote and distribute its vaccine brands across private markets in India.

Under the arrangement confirmed on March 27, 2024, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's well-established and trusted pediatric and adult vaccine brands Hexaxim®, Pentaxim®, Tetraxim®, Menactra®, FluQuadri®, Adacel®, and Avaxim® 80U.

Sanofi will continue to own, manufacture, and import these brands into India.

These brands saw combined sales of approximately $51 million as of February 2024.

M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy's, commented in a press release, "We are happy to have the opportunity to leverage our strengths in promotion and distribution to considerably expand engagement with healthcare professionals and help widen access of Sanofi's well-established and trusted vaccine brands in India."

"The portfolio now gives Dr. Reddy's a strong presence in the vaccine segment, propelling us to the second position among vaccine players in India. Through each product and partnership, we aim to serve over 1.5 billion patients by 2030."

Dr. Reddy's was established in 1984 and has become a global pharmaceutical company headquartered in Hyderabad, India.

The U.S. CDC recommends visiting your healthcare provider at least a month before visiting India to get any vaccines or medicines you may need.

Additionally, the CDC included India in its recent Global Measles travel advisory.